



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Salmonson, Roger  
Serial No.: 10/608,744  
Filed: June 27, 2003  
For: TOPICAL ANALGESICS AND METHODS OF USE  
Examiner: Michele Flood  
Group: 1655  
Docket No. 17595-00005

Mail Stop: AF  
Commissioner of Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**DECLARATION OF ROGER SALMONSON**

I, Roger Salmonson, declare,

1. I am the inventor of the topical analgesics and methods of use that are the subject of U.S. Patent Serial No. 10/608,744, referred to above.

2. I am also the president of Claire Ellen Products, which sells the topical analgesic, sold under the trademark Menastil®, which is the topical analgesic disclosed and claimed in the subject application.

3. Since the first commercial offering of Menastil® topical analgesic, the product has enjoyed tremendous commercial success and received outstanding accolades and interest in the industry.


4. In just the past two years alone, Claire Ellen Products has shipped 30,000 orders of Menastil® topical analgesic. The average retail price for the product is \$24.95 for a 1/8 ounce bottle.

5. In addition to instantaneous commercial success of the product, Menastil® topical analgesic has received accolades from various recognized authorities in the industry. For example, attached is a general letter of recommendation for the product

from Mary Lou Ballweg, the president and executive director of the Endometriosis Association. As a further example, Dr. Victor E. Silverman, MD, FACP, FACE, a world renown endocrinologist and the Chief of the Endocrine Section of Saint Joseph's Hospital in Atlanta has touted the topical analgesic effects of the Menastil® topical analgesic.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Date: March 20, 2006

  
Roger Salmonson